[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fallopian-tube-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fallopian-tube-cancers":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,44,76,107,142,171,193,222,250,263,291],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100054111","phase-1-catalina-4-a-study-to-investigate-the-safety-and-efficacy-of-torl-1-23-with-chemotherapy-given-before-initial-surgery-in-women-with-advanced-stage-ovarian-cancer-100054111",false,"NCT07322094","CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer","CATALINA-4: Phase 1B\u002F2 Study of TORL-1-23 With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Newly Diagnosed Patients With Advanced Stage Ovarian Cancer","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1\n* Histologically or cytologically confirmed diagnosis of epithelial ovarian, primary peritoneal or fallopian tubes cancer\n* FIGO Stage III or IV\n* Positive for claudin 6 (CLDN6) expression\n* Adequate organ function\n\nExclusion Criteria:\n\n* Clear cell, mucinous, sarcomatous, mixed histology, low-grade\u002Fborderline, or non-epithelial ovarian cancers\n* Prior systemic treatment for the disease under study\n* Prior surgery\n* Prior radiation therapy to the abdomen or pelvis\n* Current recipient or receipt within 5-half-lives of C1D1 of any of the following: chemotherapy, biologic\u002Ftargeted therapy, herbal medications or supplements, immunomodulator therapy for any disease indication.\n* History of noninfectious pneumonitis\u002Finterstitial lung disease (ILD) within 6 months of first dose of study drug.\n* Active, progressive, or symptomatic brain metastases\n* Participants considered poor medical risks due to serious, uncontrolled medical conditions, active infections, or nonmalignant systemic diseases\n* Pregnant or breastfeeding women","FEMALE","18 Years","75 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","A Phase 1B\u002F2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer",[28,29,30],"FIGO Stage III and IV Ovarian Cancer","Fallopian Tube Cancers","Primary Peritoneal Cancer","RECRUITING","2026-07-09",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2025-12-10",{"date":39,"type":21},"2028-01",{"name":41,"class":42},"TORL Biotherapeutics, LLC","INDUSTRY",7,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100644807","phase-1-immu-132-in-trop-2-overexpressed-advanced-and-relapsed-ovarian-cancer-100644807","NCT07674615","IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer","IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer: A Phases Ib, Single Arm Study","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 80 years;\n* Histologically confirmed advanced or recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer;\n* Recurrent patients meeting one of the following two conditions:\n\nDisease recurrence or progression after at least one prior platinum-based chemotherapy regimen, with disease progression occurring less than 6 months from the last dose of platinum-based chemotherapy;\n\n* Disease recurrence or progression after at least three prior platinum-based chemotherapy regimens, with disease progression occurring ≥ 6 months from the last dose of platinum-based chemotherapy, and who are unable to receive standard platinum-based chemotherapy;\n* Patients with advanced epithelial ovarian cancer presenting with hematogenous metastasis, who are unable to receive standard treatment, with an estimated life expectancy of more than 3 months but approximately not exceeding 12 months with current therapy;\n* Have measurable disease per RECIST 1.1 criteria (Appendix A) or diagnosis of recurrence\u002Fdisease progression per GCIG criteria;\n* Known BRCA (Breast Cancer Gene) and HRD (Homologous Recombination Deficiency) status;\n* Have available paraffin-embedded or fresh tumor tissue for TROP-2 testing;\n* Tumor tissue TROP-2 H-score \\> 200;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;\n* Adequate bone marrow hematopoietic function and organ function, allowing the patient to receive treatment;\n* Patients must have had at least a 2-week interval from prior therapy (chemotherapy, investigational agents including small molecule inhibitors, endocrine therapy, immunotherapy, and\u002For radiotherapy) or major surgery;\n* Patients must have had at least a 2-week interval from high-dose systemic corticosteroids (however, low-dose corticosteroids \\\u003C 20 mg prednisone or its equivalent are permitted);\n* Patients must have recovered from acute toxicity due to prior therapy to Grade 1 or below;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients who have previously received topoisomerase I inhibitor therapy;\n* Patients with known hypersensitivity to the study drug, its metabolites, or formulation excipients;\n* Patients requiring ongoing treatment or prior use of any prohibited medications (e.g., UGT1A1 inhibitors);\n* Patients with Gilbert's syndrome;\n* Patients with other uncontrolled malignancies concurrently or within 5 years, whose treatment would interfere with the current therapy for recurrent ovarian cancer or affect the prognosis of this treatment. Carcinoma in situ and breast cancer (without active disease or signs of recurrence) are excluded;\n* Patients with a history of clinically significant hemorrhage, bowel obstruction, or gastrointestinal perforation within 6 months prior to the start of study treatment, with an estimated life expectancy of less than 3 months;\n* Patients with a history of significant cardiac disease within 6 months, such as uncontrolled hypertension, unstable angina, uncontrolled congestive heart failure (NYHA Class III-IV), or clinically significant arrhythmias requiring antiarrhythmic therapy (except stable atrial fibrillation);\n* Patients with known clinically significant active chronic obstructive pulmonary disease (COPD) or other moderate-to-severe chronic respiratory disease within 6 months;\n* Patients with known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Patients with treated brain metastases may participate provided they have stable CNS disease for at least 4 weeks prior to the first dose, have all neurological symptoms returned to baseline, have no evidence of new or enlarging brain metastases, and are on a daily dose of ≤ 20 mg prednisone or its equivalent. All patients with carcinomatous meningitis are excluded regardless of clinical stability;\n* Patients with uncontrolled seizure history or active neurologic disorders; Patients with known HIV-1 or HIV-2 (or HIV-1\u002F2 antibody positive) with detectable viral load, or those taking medications that may interfere with SN-38 metabolism;\n* Patients with active HBV or HCV. For patients with a history of HBV or HCV, those with detectable viral load will be excluded;\n* Patients with known bleeding diathesis or active bleeding disorders;\n* Patients with active ≥ Grade 2 anorexia, nausea, or vomiting, and\u002For signs of bowel obstruction;\n* Patients with other concurrent medical or psychiatric conditions that, in the investigator's opinion, may confound study interpretation or prevent completion of study procedures and follow-up examinations;\n* Patients with any unstable medical problems (including the cardiac issues mentioned above, active treatment for symptomatic pulmonary embolism, stroke, renal or hepatic insufficiency, active infection\u002Fsepsis requiring intravenous antibiotics);\n* Any medical condition that, in the investigator's opinion, poses an undue risk to the patient's participation in the study.","80 Years",{"count":53,"type":21},19,[24],"To observe the efficacy and safety of IMMU-132 in patients with advanced or recurrent ovarian cancer with high TROP-2 expression in tumor tissue, who have failed standard therapy or are unable to receive standard treatment.",[57,29,58,59],"Epithelial Ovarian Cancer","Primary","Primary Peritoneal Carcinoma",[61,62,63],"Ovarian cancer","TROP2","Antibody-drug conjugates","NOT_YET_RECRUITING","2026-06-28",{"date":67,"type":35},"2026-06-30",{"date":69,"type":21},"2026-07-01",{"date":71,"type":21},"2027-06-30",{"name":73,"class":74},"Shanghai Gynecologic Oncology Group","OTHER_GOV",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100568573","phase-2-a-study-to-assess-adverse-events-and-change-in-disease-activity-in-participants-with-platinum-resistant-advanced-high-grade-epithelial-ovarian-primary-peritoneal-or-fallopian-tube-cancers-with-high-folate-receptor-alpha-expression-treated-with-intravenously-iv-infused-mirvetuximab-soravtansine-100568573","NCT06682988","A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine","A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment","Inclusion Criteria:\n\nBoth Cohorts\n\n* Participants with a confirmed diagnosis of high-grade serous epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer.\n* Participants with platinum-resistant disease:\n\n  * Participants with 1 prior line of platinum-based therapy who have received ≥ 4 cycles of platinum and had a response (complete response (CR) or partial response (PR)) followed by radiological progressive disease (PD) between \\> 3 months and ≤ 6 months after the date of the last dose of platinum.\n  * Participants with 2 or 3 prior lines of platinum-based therapy who had radiological PD ≤ 6 months after the date of the last dose of platinum.\n* Participants with progression diagnosed radiographically on or after their most recent line of therapy.\n* Participants with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.\n* Participants with ≥ 1 lesion that meets the definition of measurable disease by RECIST v1.1 (radiologically measured by the investigator).\n* Participants with a tumor that is positive for folate receptor alpha (FRα) expression as determined by the Ventana folate receptor 1 (FOLR1) assay (≥ 75% of tumor staining at 2+ intensity).\n\nExclusion Criteria:\n\nBoth Cohorts\n\n* Participants with endometrioid, clear cell, mucinous, or sarcomatous histology; mixed tumors containing any of the above histologies; or low-grade or borderline ovarian tumor.\n* Participants with primary platinum-refractory disease, defined as disease that did not respond (complete response (CR) or partial response (PR)) or that progressed radiographically within 3 months of the last dose of first-line platinum-containing chemotherapy.\n* Participants with serious concurrent illness or clinically relevant active infection as outlined in the protocol\n* Participants with a history of hemorrhagic or ischemic stroke within 6 months prior to randomization.",{"count":84,"type":21},110,[25],"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of for Mirvetuximab Soravtansine in participants with platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer (platinum-resistant ovarian cancer) (PROC) whose tumors express a high level of folate receptor alpha (FRα).\n\nMirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). There are 2 cohorts in this study, the Randomized Phase 2 Cohort and the Hepatic Impairment Cohort. In the Randomized Phase 2 Cohort, participants are placed in 1 of 2 groups, called treatment arms. Each treatment arm receives MIRV on a different schedule (on day 1 every 21 days or on days 1 and 15 every 28 days). The Hepatic Impairment Cohort is designed to determine the starting dose of MIRV in patients with moderately abnormal liver function. Around 110 participants will be enrolled in the study at approximately 75 sites worldwide.\n\nThe total study duration will be approximately 24 months.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.",[88,30,29],"Advanced High-Grade Epithelial Ovarian Cancer",[90,91,29,92,93,94,95,96],"Advanced High-Grade Epithelial Ovarian","Primary Peritoneal","High Folate Receptor-Alpha Expression","Platinum Resistant","Mirvetuximab Soravtansine","MIRV","IMGN853","2026-05-21",{"date":99,"type":35},"2026-05-26",{"date":101,"type":35},"2025-05-28",{"date":103,"type":21},"2028-04",{"name":105,"class":42},"AbbVie",52,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":4},"100638290","phase-2-liposomal-irinotecan-plus-enlonstobart-for-platinum-resistant-recurrent-ovarian-cancer-100638290","NCT07591831","Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer","An Exploratory Clinical Study of Liposomal Irinotecan Combined With Enlonstobart in Patients With Platinum-Resistant Recurrent Ovarian Cancer","Inclusion Criteria:\n\n1. Female participants aged 18 to 75 years, inclusive, at the time of signing informed consent.\n2. Histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, FIGO stage II-IV.\n3. Platinum-resistant recurrent disease, defined as disease progression within 6 months after the last platinum-containing chemotherapy, and not platinum-refractory disease, defined as disease progression within 4 weeks after initial platinum-containing chemotherapy. Participants may have received up to two prior lines of non-platinum systemic therapy. Treatment with a PARP inhibitor or anti-angiogenic therapy after platinum-resistant recurrence will be counted as one line of therapy; maintenance treatment with a PARP inhibitor or anti-angiogenic therapy will not be counted as a treatment line.\n4. Ability to provide sufficient qualified formalin-fixed paraffin-embedded tumor tissue samples or slides for PD-L1 testing. Participants who are unable to provide tumor tissue slides for certain reasons may be enrolled at the investigator's discretion.\n5. At least one measurable lesion at baseline according to RECIST version 1.1. The measurable lesion must not have received prior local therapy such as radiotherapy. A lesion located within a previously irradiated area may be selected as a target lesion if disease progression has been confirmed.\n6. ECOG performance status of 0 or 1.\n7. Expected survival of at least 3 months.\n8. Adequate organ function, meeting all of the following criteria without blood transfusion, hematopoietic stimulating factors, or medication correction of blood cell counts within 14 days before the first dose:\n\n   1. Absolute neutrophil count ≥1.5 × 10\\^9\u002FL;\n   2. Platelet count ≥75 × 10\\^9\u002FL;\n   3. Hemoglobin ≥9 g\u002FdL;\n   4. Serum creatinine ≤1.5 × the upper limit of normal or creatinine clearance ≥50 mL\u002Fmin;\n   5. Total bilirubin ≤1.5 × the upper limit of normal, or ≤3 × the upper limit of normal for participants with Gilbert's syndrome;\n   6. Alanine aminotransferase and aspartate aminotransferase ≤2.5 × the upper limit of normal, or ≤5 × the upper limit of normal for participants with liver metastases;\n   7. Activated partial thromboplastin time and international normalized ratio ≤1.5 × the upper limit of normal, without anticoagulants or other drugs affecting coagulation function within 14 days before the first dose, except for participants requiring long-term anticoagulation due to underlying disease.\n9. Toxicities caused by prior antitumor therapy must have recovered to Grade 1 or lower according to CTCAE version 5.0, except for residual alopecia and fatigue.\n10. Participants must understand the study and voluntarily sign written informed consent before study entry.\n\nExclusion Criteria:\n\n1. History of severe hypersensitivity reaction to monoclonal antibody preparations or uncontrolled allergic asthma.\n2. Known untreated central nervous system metastases, or treated but still symptomatic central nervous system metastases. Participants with residual signs or symptoms related to central nervous system treatment may be eligible if neurological symptoms have been stable or improved for at least 2 weeks before screening.\n3. History of primary immunodeficiency.\n4. Active autoimmune disease or history of autoimmune disease. Participants with well-controlled type 1 diabetes mellitus, well-controlled hypothyroidism requiring only hormone replacement therapy, skin diseases not requiring systemic treatment such as vitiligo, psoriasis, or alopecia, or conditions not expected to recur without external triggers may be eligible for further screening.\n5. Serious arterial or venous thrombotic events within 3 months before screening, such as transient ischemic attack, cerebral hemorrhage, cerebral infarction, deep venous thrombosis, or pulmonary embolism.\n6. History of interstitial lung disease, except localized radiation-induced interstitial pneumonia, or noninfectious pneumonia requiring glucocorticoid therapy.\n7. Prior treatment with any antibody or drug targeting T-cell costimulatory or immune checkpoint pathways, including PD-1, PD-L1, PD-L2, CTLA-4, OX40, or CD137 inhibitors.\n8. Prior immune-related adverse event of CTCAE version 5.0 Grade 3 or higher after immunotherapy.\n9. Major surgery or radical radiotherapy within 28 days before the first dose; palliative radiotherapy within 14 days before the first dose; or use of radiopharmaceuticals such as strontium or samarium within 56 days before the first dose.\n10. Systemic antitumor therapy within 28 days before the first dose, including but not limited to chemotherapy, immunotherapy, macromolecular targeted therapy, or biological therapy such as tumor vaccines, cytokines, or growth factors used to control cancer. Small-molecule targeted therapy or oral fluoropyrimidines within 14 days before the first dose or within 5 half-lives, whichever is longer; or mitomycin C or nitrosoureas within 6 weeks before the first dose.\n11. Receipt of a live attenuated vaccine within 28 days before the first dose or planned receipt of a live attenuated vaccine during the study.\n12. Any active infection requiring systemic treatment by intravenous infusion within 28 days before the first dose.\n13. Treatment within 14 days before the first dose with traditional Chinese patent medicines approved by the NMPA whose package inserts clearly state antitumor indications, or traditional Chinese herbal medicine documented in the medical record as being used for antitumor purposes.\n14. Whole blood or blood component transfusion within 14 days before the first dose.\n15. Treatment with glucocorticoids equivalent to prednisone \\>10 mg\u002Fday or other immunosuppressive agents within 14 days before the first dose.\n16. Participation in another clinical trial and receipt of investigational treatment within 28 days before the first dose, calculated from the date of the last treatment in the previous clinical study, except participation in overall survival follow-up of a study.\n17. Positive human immunodeficiency virus antibody or Treponema pallidum antibody; positive hepatitis B surface antigen and\u002For hepatitis B core antibody with hepatitis B virus DNA above the upper limit of normal of the testing laboratory; or positive hepatitis C antibody with hepatitis C virus RNA above the upper limit of normal of the testing laboratory.\n18. History of active tuberculosis.\n19. Pregnancy or breastfeeding.\n20. Other malignancy that progressed or required treatment within 5 years before screening, except adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or cured carcinoma in situ such as breast carcinoma in situ.\n21. Any other condition that may increase the risk associated with study treatment, interfere with interpretation of study results, affect study compliance, or otherwise make the participant unsuitable for the study in the investigator's judgment.\n22. Any clinically significant gastrointestinal disease, including liver disease, bleeding, inflammation, obstruction, or diarrhea greater than Grade 2.\n23. Current use or use within the past 2 weeks of strong CYP3A enzyme inducers or inhibitors and\u002For strong UGT1A inhibitors.\n24. Prior use of liposomal irinotecan formulation or irinotecan.\n25. Any condition that, in the investigator's judgment, makes the participant unsuitable for this study.",{"count":115,"type":21},30,[25],"This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of liposomal irinotecan combined with enlonstobart in patients with platinum-resistant recurrent ovarian cancer.\n\nEligible female participants with histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, FIGO stage II-IV, will receive liposomal irinotecan and enlonstobart every 2 weeks. Tumor assessment will be performed every 8 weeks. Participants may discontinue study treatment in the event of disease progression, intolerable toxicity, withdrawal of consent, or other reasons judged by the investigator.",[119,29,57,30],"Platinum-resistant Recurrent Ovarian Cancer",[121,122,123,124,125,126,127,128,129,130,131],"Platinum-resistant ovarian cancer","Recurrent ovarian cancer","Epithelial ovarian cancer","Fallopian tube cancer","Primary peritoneal cancer","Liposomal irinotecan","Enlonstobart","PD-1 inhibitor","Objective response rate","Progression-free survival","Overall survival","2026-05-15",{"date":134,"type":35},"2026-05-18",{"date":136,"type":21},"2026-05-30",{"date":138,"type":21},"2030-05-30",{"name":140,"class":141},"Tianjin Medical University Cancer Institute and Hospital","OTHER",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100630563","phase-2-benmelstobart-in-combination-with-anlotinib-and-oral-metronomic-cyclophosphamide-in-the-treatment-of-recurrent-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer-100630563","NCT07489300","Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer","BACON","Inclusion Criteria:\n\n* 1.The age on the day of signing the informed consent form is 18 years or older. 2.Eastern Cooperative Oncology Group performance status of 0-1, with the ability to tolerate chemotherapy.\n\n  3.There is measurable disease according to the RECIST 1.1 or irRECIST criteria. 4.The histological types can be serous, endometrioid, clear cell, mucinous or undifferentialed types of recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. The original primary tumor needs to be histologically confirmed through the pathological report.\n\n  5.Participants can be either platinum-sensitive (with a platinum-free interval(PFI) of ≥6 months before the recent recurrence) or platinum-resistant (with a PFI of \\\u003C6 months before the recent recurrence). If the participant has a platinum-sensitive disease, they can only participate in this clinical trial with platinum-based chemotherapy contraindications (such as severe persistent toxicity or a severe hypersensitivity reaction to platinum drugs, or refuse standard treatment).\n\n  6.The participants must be willing to undergo hollow needle biopsy or excisional biopsy of tumor lesion within 4 weeks (28 days) before the start of the treatment and after 3 cycles treatment. For participants who are unable to provide new samples (for example, unable to obtain or there are issues related to the safety of the participants), only with the consent of the principal investigator can archived samples be submitted.\n\nExclusion Criteria:\n\n\\-",{"count":150,"type":21},40,[25],"Efficacy and safety of Benmelstobart combined with Anlotinib and oral metronomic Cyclophosphamide in the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer (BACON study) in China",[154,29,30],"Ovarian Cancer",[156,157,158,159,160,161],"Benmelstobart","Anlotinib","oral metronomic Cyclophosphamide","epithelial ovarian cancer","fallopian tube cancer","primary peritoneal cancer","2026-03-19",{"date":164,"type":35},"2026-03-24",{"date":166,"type":21},"2026-03-30",{"date":168,"type":21},"2028-01-31",{"name":170,"class":141},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":75},"100629243","phase-2-parp-poly-adp-ribose-polymerase-inhibitor-with-or-without-angiogenesis-inhibitor-in-homologous-recombination-deficient-primary-ovarian-cancer-fallopian-tube-cancer-or-primary-peritoneal-cancer-100629243","NCT07472140","PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer","To Develop and Implement The Scope of Medical Care for Homologous Recombination Deficient Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer of the III-IV Stages Using Maintenance Therapy With PARP Inhibitor Combined With Angiogenesis Inhibitor.","Inclusion Criteria:\n\n* Age ≥18-≤75 years.\n* Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Possibility of performing diagnostic laparoscopy or cytoreductive surgery.\n* Presence of homologous recombination deficiency (HRD).\n* No contraindications to chemotherapy, or bevacizumab.\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Presence of another active malignant invasive neoplasm.\n* Pregnancy or lactation period.\n* Disease progression during treatment.",{"count":179,"type":21},120,[25,181],"PHASE3","This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.",[154,29,30],"2026-03-11",{"date":186,"type":35},"2026-03-16",{"date":188,"type":35},"2025-07-01",{"date":190,"type":21},"2033-06-30",{"name":192,"class":74},"N.N. Alexandrov National Cancer Centre",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":4},"100626204","phase-2-neoadjuvant-aitua-pd-1ctla-4-bispecific-plus-nab-paclitaxel-and-carboplatin-for-advanced-high-grade-serous-ovarian-cancer-100626204","NCT07432594","Neoadjuvant Aitua (PD-1\u002FCTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer","A Prospective, Randomized, Controlled Phase II Clinical Study of Albumin-Bound Paclitaxel\u002FCarboplatin Combined With Aitua Combination Antibody (PD-1\u002FCTLA-4 Bispecific Antibody) for the Neoadjuvant Treatment of Advanced High-Grade Serous Ovarian Cancer With Unsatisfactory Debulking","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed high-grade serous ovarian cancer (HGSC), fallopian tube cancer, or primary peritoneal cancer.\n* International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Assessed by a multidisciplinary team (MDT) based on imaging (± laparoscopic exploration) as initially unable to achieve satisfactory tumor debulking (R0 resection).\n* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.\n* Major organ function is basically normal.\n* Willing to provide tumor tissue, peripheral blood, and ascites samples for translational research.\n\nExclusion Criteria:\n\n* Pathological types other than high-grade serous carcinoma (HGSC).\n* Prior receipt of any form of anti-tumor therapy.\n* History of autoimmune disease or requiring immunosuppressive therapy.\n* Known allergy to study drug components.\n* Pregnant or lactating women.",{"count":201,"type":21},82,[25],"This is a prospective, randomized, controlled Phase II clinical study designed to evaluate the efficacy and safety of adding Aitua Combination Antibody (a PD-1\u002FCTLA-4 bispecific antibody) to standard neoadjuvant chemotherapy for patients with advanced high-grade serous ovarian cancer.\n\nThe study focuses on patients who are newly diagnosed with Stage IIIC-IV ovarian, fallopian tube, or primary peritoneal cancer and are assessed as unable to achieve satisfactory tumor debulking (R0 resection) initially.\n\nParticipants will be randomized in a 1:1 ratio into two groups:\n\nExperimental Group: Receives Nab-paclitaxel and Carboplatin combined with Aitua Combination Antibody.\n\nControl Group: Receives Nab-paclitaxel and Carboplatin alone.\n\nBoth groups will receive 3 cycles of neoadjuvant treatment followed by Interval Debulking Surgery (IDS). The primary goal is to compare the R0 resection rate (complete removal of macroscopic tumor) between the two groups during surgery. Secondary goals include assessing pathological complete response (pCR), objective response rate, progression-free survival, and safety. The study also aims to explore how this combination therapy affects the tumor immune microenvironment.",[205,29,30],"High-grade Serous Ovarian Cancer (HGSOC)",[207,208,209,210,211,212,213],"Neoadjuvant Chemotherapy","Interval Debulking Surgery","PD-1\u002FCTLA-4 Bispecific Antibody","Aitua Combination Antibody","Nab-paclitaxel","Carboplatin","Immunotherapy","2026-02-21",{"date":216,"type":35},"2026-02-25",{"date":218,"type":21},"2026-03-01",{"date":71,"type":21},{"name":221,"class":141},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":228,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":233,"conditions":234,"keywords":239,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":75},"100620786","exploring-the-effects-of-hand-and-foot-exercise-intervention-in-older-adults-with-gynecological-cancer-receiving-chemotherapy-improvement-of-peripheral-neuropathy-and-quality-of-life-100620786","NCT07362147","Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of Life","Inclusion Criteria:\n\nIndividuals aged 65 or older diagnosed with gynecological cancer (stage II to IV) by a physician, without skin or nail lesions.\n\nIndividuals who have received at least one course of chemotherapy within the past year and have peripheral neuropathy, with chemotherapy drugs including paclitaxel (Paclitaxel or Docetaxel) or platinum-based drugs (Cisplatin or Carboplatin), and may receive combined targeted or immunotherapy.\n\nIndividuals who are conscious and able to communicate in Mandarin, Taiwanese, or written language.\n\nExclusion Criteria:\n\nSkin or nail lesions. Edema of 3+ or more in the extremities. History of diagnosis of diabetes, neuropathy, peripheral arterial ischemia, or multiple organ failure.\n\nDistal bone or skin metastases. Patients who have interrupted chemotherapy. Patients who have participated in similar studies.","65 Years",{"count":230,"type":21},74,[232],"NA","Paclitaxel-based drugs are commonly used adjuvant chemotherapy for gynecological cancer patients. Peripheral neuropathy, a side effect of this treatment, presents with symptoms such as numbness, tingling, decreased skin and reflex sensation, and impaired function in the hands and feet, thus affecting quality of life. Peripheral neuropathy is a side effect caused by the neurotoxicity of certain chemotherapeutic drugs, including paclitaxel and platinum-based drugs, resulting from the cumulative toxicity of specific drug doses. While numerous international studies have confirmed the preventative effects of hand and foot movement interventions, there is a lack of relevant literature in China. Therefore, this study aims to explore the effects of hand and foot movement interventions on elderly gynecological cancer patients undergoing chemotherapy.",[235,236,237,154,238,29],"Peripheral Neuropathy","Cervical Cancer","Endometrial Cancer","Vaginal Cancers",[240],"hand and foot exercises, chemotherapy, gynecological cancer, peripheral neuropathy, quality of life","2026-01-21",{"date":243,"type":35},"2026-01-23",{"date":245,"type":21},"2026-01-01",{"date":247,"type":21},"2027-11-30",{"name":249,"class":74},"Taipei Veterans General Hospital, Taiwan",{"id":251,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":26,"conditions":256,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":261,"leadSponsor":262,"locationsCount":75},"100617705","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.\n* Histologically or cytologically confirmed diagnosis of epithelial ovarian, primary peritoneal or fallopian tubes cancer\n* FIGO Stage III or IV\n* Positive for claudin 6 (CLDN6) expression\n* Adequate organ function\n\nExclusion Criteria:\n\n* Clear cell, mucinous, sarcomatous, mixed histology, low-grade\u002Fborderline, or non-epithelial ovarian cancers\n* Prior systemic treatment for the disease under study\n* Prior surgery\n* Prior radiation therapy to the abdomen or pelvis\n* Current recipient or receipt within 5-half-lives of C1D1 of chemotherapy, biologic\u002Ftargeted therapy, immunomodulator therapy for any disease indication\n* Active, progressive, or symptomatic brain metastases\n* Participants considered poor medical risks due to serious, uncontrolled medical conditions, active infections, or nonmalignant systemic diseases\n* Pregnant or breastfeeding women","70 Years",{"count":20,"type":21},[24,25],[28,29,30],"2026-01-05",{"date":259,"type":35},"2026-01-07",{"date":37,"type":35},{"date":39,"type":21},{"name":41,"class":42},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":270,"targetDuration":4,"studyType":272,"phases":4,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":4},"100613667","impact-of-dietary-patterns-on-prognosis-of-ovarian-cancer-patients-during-parpi-maintenance-100613667","NCT07269574","Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance","A Multicenter, Retrospective Clinical Study Evaluating the Effect of Different Dietary Patterns on the Prognosis of Ovarian Cancer Patients During PARPi Maintenance Therapy","Inclusion Criteria:\n\n* Female patients aged 18 to \\\u003C75 years.\n* Histologically or cytologically diagnosed with primary high-grade serous ovarian cancer (HGSOC), fallopian tube cancer, or primary peritoneal cancer.\n* Received initial tumor cytoreductive surgery (Primary Debulking Surgery or Interval Debulking Surgery) and first-line platinum-based chemotherapy, achieving Complete Response (CR) or Partial Response (PR).\n* Received PARP inhibitors as maintenance therapy for the first time following the completion of first-line treatment.\n* Complete clinical data available in the electronic medical records, including baseline characteristics, first-line treatment details, PARPi maintenance therapy information, and prognostic follow-up data.\n* The patient (or primary caregiver) has normal communication abilities, voluntarily agrees to participate, and is able to cooperate in completing the retrospective Food Frequency Questionnaire (FFQ).\n\nExclusion Criteria:\n\n* Clinical diagnosis only, without pathological or cytological confirmation.\n* Non-high-grade serous histological subtypes (e.g., ovarian clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, low-grade serous carcinoma).\n* Secondary or metastatic ovarian cancer (malignancy originating from other organs).\n* Severe deficiency of key clinical or prognostic information that prevents assessment of the primary endpoint.\n* Inability to accurately recall dietary information due to cognitive impairment, mental illness, or other reasons.\n* Presence of severe metabolic or digestive system diseases during PARPi maintenance therapy that required specific restricted diets (e.g., insulin-dependent diabetes, dialysis-dependent renal insufficiency, short bowel syndrome, active Crohn's disease).\n* Occurrence of significant physiological events during the study period that significantly altered dietary structure (e.g., major gastrointestinal surgery).",{"count":271,"type":21},600,"OBSERVATIONAL","The goal of this retrospective observational study is to evaluate the relationship between different dietary patterns (specifically low-carbohydrate diets) and the prognosis of patients with high-grade serous ovarian cancer (HGSOC) receiving first-line PARP inhibitor (PARPi) maintenance therapy. The main questions it aims to answer are:\n\n* Is there an association between dietary patterns and patients' Progression-Free Survival (PFS)?\n* Is there an association between dietary patterns and Overall Survival (OS)? This is a multicenter, retrospective cohort study. Researchers will review electronic medical records from 14 tertiary hospitals in China to identify women who received first-line PARP inhibitor maintenance for advanced high-grade serous ovarian cancer between 2020 and 2025, and collect information on baseline characteristics, treatments and follow-up outcomes.\n\nResearchers will compare patients with a \"low-carbohydrate diet pattern\" to those with a \"regular\u002Fhigh-carbohydrate diet pattern\" to see if there are differences in treatment outcomes and survival.\n\nParticipants will:\n\n* Have their clinical, pathological, and treatment data collected from electronic medical records.\n* Complete a retrospective Food Frequency Questionnaire (FFQ) via phone or clinic visit to recall their dietary habits during the maintenance treatment period.\n* Optionally provide a blood sample for nutrition and metabolic analysis. (For participants at the main study center only) No experimental drugs or specific diets will be given in this study. All anti-cancer treatments are decided by the treating physicians as part of routine clinical care.",[154,29,59,275],"High-grade Serous Ovarian Cancer",[154,277,278,279,280,281],"High-Grade Serous Ovarian Cancer","PARP Inhibitor","Maintenance Therapy","Dietary Pattern","Low-Carbohydrate Diet","2025-11-26",{"date":284,"type":35},"2025-12-08",{"date":286,"type":21},"2025-11-27",{"date":288,"type":21},"2026-12-31",{"name":290,"class":141},"Tongji Hospital",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":301,"conditions":302,"keywords":303,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":4},"100573838","phase-3-jskn003-in-platinum-resistant-relapsed-epithelial-ovarian-cancer-100573838","NCT06751485","JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer","A Randomized, Open-Label, Parallel-Controlled, Multi-center Phase Ⅲ Study of JSKN003 Versus Investigator-Choice Chemotherapy for Platinum-Resistant, Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","Inclusion Criteria:\n\n* Voluntary participation and written informed consent.\n* ≥18 years;\n* Histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.\n* Confirmed platinum-resistant relapse.\n* According to RECIST 1.1 criteria, there must be at least one measurable lesion in the baseline.\n* Expected survival of more than 3 months.\n* ECOG performance status score of 0 or 1.\n* Adequate organ function.\n* Capable and willing to comply with the study protocol, treatment plan, laboratory tests, and other related study procedures.\n\nExclusion Criteria:\n\n* Primary platinum-refractory disease.\n* Active central nervous system metastases.\n* Uncontrolled pleural effusion.\n* Previous treatment with topoisomerase I inhibitor ADCs.\n* Other malignant tumors within 5 years.\n* Interstitial pneumonia\u002Flung disease requiring systemic corticosteroids or suspected interstitial pneumonia\u002Flung disease.\n* Uncontrolled comorbidities.\n* Toxicity from previous anti-cancer treatments not recovered to CTCAE Grade ≤1.\n* History of allogeneic bone marrow or organ transplantation.\n* Allergic reactions or hypersensitivity to antibody drugs.\n* Conditions affecting study drug treatment safety or compliance, including psychiatric disorders, alcohol abuse, or drug abuse.",{"count":299,"type":21},430,[181],"This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN003 versus investigator's choice of chemotherapy in patients with platinum-resistant, relapsed epithelial Ovarian, primary peritoneal, or fallopian tube cancer.",[154,91,29],[304],"JSKN003-306","2024-12-27",{"date":307,"type":35},"2024-12-31",{"date":309,"type":21},"2025-01-15",{"date":311,"type":21},"2027-12-30",{"name":313,"class":42},"Jiangsu Alphamab Biopharmaceuticals Co., Ltd"]